Market Segmentation:
- By Product Type
- Exenatide
- Liraglutide
- Semaglutide
- Dulaglutide
- Lixisenatide
- By Route of Administration
- Injectable
- Oral
- Others (Inhaled, Transdermal)
- By Drug Classification
- Short-acting
- Long-acting
- Others (Ultra-long-acting)
- By Application
- Type 2 Diabetes
- Obesity
- Others (Polycystic Ovary Syndrome, Non-alcoholic Steatohepatitis)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Mail-order Pharmacies, Specialty Pharmacies)
- By End-User
- Hospitals
- Clinics
- Homecare Settings
- Others (Research Institutes, Academic Institutions)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Glucagon-Like Peptide 1 (GLP-1) Drugs industry is US$ 8.2 billion.
Rising prevalence of type 2 diabetes, increasing obesity rates, aging global population, favorable reimbursement policies, development of novel drug formulations, expanding therapeutic applications, growing awareness about diabetes management, and increasing healthcare expenditure.
High treatment costs, safety concerns, stringent regulatory requirements, side effect profile, limited access to healthcare in some regions, and competition from alternative therapies.
The leading component segment in the Glucagon-Like Peptide 1 (GLP-1) Drugs Market is semaglutide, a once-weekly injectable GLP-1 agonist used for type 2 diabetes treatment.
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, and Janssen Pharmaceuticals, Inc. (Johnson & Johnson).
The North America region is expected to lead the Glucagon-Like Peptide 1 (GLP-1) Drugs Market, with a CAGR of 12.1% and a market size of US$ 18.2 billion by 2030.
Rising prevalence of type 2 diabetes, increasing obesity rates, aging global population, favorable reimbursement policies, development of novel drug formulations, expanding therapeutic applications, and growing awareness about diabetes management.